How to Determine Product Classification for Medical Device Registration in Vietnam?

Key Summary

To determine product classification for medical device registration in Vietnam, companies should first confirm the target country, product risk level, applicable regulatory pathway, and existing documentation basis, then evaluate technical files, quality system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first conduct product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Vietnam registration typically affects technical files, authorized representative, importer cooperation, label language, quality system certification, and subsequent change maintenance. If the project is advanced only based on 'what documents to submit,' corrections or rework are likely in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends integrating this issue into a unified GHWP member state and multi-country market access strategy, using a reusable core technical file to support localization in different markets, rather than redoing documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for 'how to determine product classification for medical device registration in Vietnam' are usually not seeking a conceptual explanation, but rather to assess whether existing documentation can support a Vietnam submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities simultaneously.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, or Latin America simultaneously, answering the process for just one country is not enough. A more valuable approach is to first create reusable versions of core technical files, quality system certifications, performance verification, clinical evidence, and labels/IFU, then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, usage scenario, method of body contact, duration of use, sterility, whether it is active, and whether it contains software or IVD attributes, then determine the risk level and submission pathway. Once the pathway is incorrectly determined, subsequent translation, notarization, authorization, testing, and supplementary documentation will deviate from the correct direction.

For Vietnam projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only vaguely addressed in commercial contracts, they can easily affect market control later.

Documentation and Evidence

Common documentation includes product description, model/specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certification, technical files, performance verification reports, risk management files, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer's declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on how many documents a company has uploaded.

Common Mistakes

The most common problem is that companies treat registration projects as simple document submissions without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documentation without rearranging evidence according to the Vietnam pathway.
• Having too many models/specifications, but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent solely based on sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistencies in claims among labels, IFU, promotional materials, and registration documents, leading to corrections or post-market compliance risks.
• Failing to plan for multi-country documentation reuse in advance, resulting in repeated preparation for each country and amplified costs and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation basis, avoiding the discovery of critical evidence gaps only after entering the submission phase.

• Compile a target product list, model/specification matrix, and intended use descriptions.
• Verify whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificates, test reports, risk management, clinical evaluation, and English IFU.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table, specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI's View

AIMEILI advises companies not to view Vietnam registration as a one-time document submission, but to manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix, then converting according to each country's requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, regulatory responsibility boundaries of local partners. As long as these three are unclear, even if documentation appears extensive, the project may still experience repeated issues during corrections, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic Chinese documentation be used directly for Vietnam registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to initiate a gap assessment?

It is recommended to initiate it immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage the product list, model/specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and estimated submission time in a single table. This allows for timely identification of documentation gaps and helps management determine whether the project will affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labels and IFU, clinical evaluation, risk management, performance verification, and quality system certificates must maintain consistent versions.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities typically check consistency among manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model specifications, IFU version, and test reports are inconsistent, even if a company has prepared extensive documentation, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and quality system certificates item by item. This action may seem basic, but it can significantly reduce the probability of corrections, especially for projects submitted simultaneously to multiple GHWP member states or with multiple product lines.

Localization Conversion and Agent Responsibilities

Vietnam registration projects typically involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU, and authorization documents also cannot be simply translated. Companies should verify local language requirements, boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest significant effort in obtaining certificates but neglect post-market maintenance. Once a manufacturing address change, model expansion, IFU update, or agent replacement occurs, the certificate may become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration planning: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, correction, post-market maintenance, and renewal milestones. The value of this is not only improving registration efficiency in a single country, but more importantly enabling companies to develop replicable global compliance capabilities and reduce the cost of starting from scratch each time they enter a new market.

Further Reading

• Previous article: How to Prepare Registration Documentation for Medical Device Registration in Vietnam?
• Next article: How to Organize Technical Files for Medical Device Registration in Vietnam?
• Recommended reading: How to Prepare Registration Documentation for Medical Device Registration in Malaysia?
• Recommended reading: How to Determine Product Classification for Medical Device Registration in Malaysia?
• Recommended reading: How to Organize Technical Files for Medical Device Registration in Malaysia?
• Recommended reading: How to Localize Labels and IFU for Medical Device Registration in Malaysia?
• Recommended reading: How to Prepare Clinical Evaluation Documentation for Medical Device Registration in Malaysia?
• Recommended reading: Can Test Reports Be Reused for Medical Device Registration in Malaysia?
• Back to FAQ Center
• News
• Contact AIMEILI

Content Review and Applicable Boundaries

• Content author: AIMEILI Regulatory Editorial Department
• Professional review: AIMEILI Medical Device International Registration Project Team
• Source principles: Prioritize official regulatory agencies, international organizations, standards organizations, and public regulatory information; industry media and project experience are for supplementary judgment only.
• Applicable boundaries: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of the target country's regulatory agency, testing conclusions, or legal advice.

Published: 2026-07-10 16:20 | Updated: 2026-07-10 16:20